 | Hey there, I hope you didn't miss my colleague Dave Lashmet's e-mail yesterday… It's the one that Porter told you to keep an eye out for. In it, Dave shared an urgent opportunity involving a biotech company that has developed a highly effective immunotherapy for Alzheimer’s disease. Our phones have been ringing non-stop since his message went out… but we haven't heard from you. Just remember, the huge opportunity Dave described yesterday is time-sensitive. Dave predicts that this company is about to go public with a major announcement regarding its new Alzheimer's drug… and expects this news could send the stock soaring as much as 100%, in a matter of weeks. His original email is below… Take a few minutes to read through it… And then call my team at 800-479-7881 when you're ready to act on this urgent opportunity. Today is your last chance to call in. My team will be standing by from 10 AM EST to 3 PM EST. I look forward to hearing from you. Sincerely, Mike Cottet
Director, Member Services
Stansberry Research
800-479-7881 From: Dave Lashmet, Stansberry Venture
June 28, 2016 10:15 AM
Dear Reader,
It starts off small.
Most people don't even notice it.
But you do.
You notice she's been losing her keys several times a week…
Struggling to come up with the right word.
And then there was Thanksgiving…
She'd talked about it months in advance. It was going to be the best ever.
She planned the menu weeks ahead of time. Asked you to taste-test her recipes, to make sure they were perfect. Invited her children and grandkids. Had everything ready to go.
You all sat down at the table…
She brought out the mashed potatoes, the casserole, the beans, the cranberry sauce, her world-famous pies…
Everything she'd promised would be there… except the turkey.
Which she forgot to buy.
She was embarrassed, of course... and you all got a good laugh out of it.
"I guess I'm not as young as I once was", she said with a smile.
But the real cause of these gaffs doesn't stay hidden for long… it gets worse.
Soon she's forgetting to shower, change her clothes, brush her teeth…
A neighbor found her wandering the grocery store parking lot… unsure of how she got there, or what she came for.
She's getting upset, sometimes downright angry, almost daily.
Not at anyone in particular… but simply because she's so confused.
Of course, nobody says anything.
They don't want her to worry, or panic.
But before long, there's only one option left…
So you're packing her clothes and her favorite trinkets… and dropping her off at an assisted living facility, where she'll get the 24/7 professional care she needs.
Every story is different… but this is a simple picture of the dreaded disease called Alzheimer's.
And it could affect anyone — your mother, your sister, your best friend…
As of today, there is no drug or treatment that's been able to slow down the advance of this fatal brain disease.
But within a matter of weeks, millions of tragic Alzheimer's stories just like this could become relics of history.
And this isn't some wild speculation on my part…
Just days ago, the same approach to a potential Alzheimer's cure — a specialized form of immunotherapy — was classified as a medical breakthrough by Europe's drug regulators.
For investors, news like this can move markets.
But so far, it hasn't.
And that's why I'm reaching out to you today…
I've uncovered one drug company that should benefit most, if this new form of treatment for Alzheimer's disease is approved.
It's also the most promising way I know of right now to potentially double your money in just a few weeks.
You see, this announcement could happen at any time.
That's why this is such an urgent opportunity.
If I had to pick a target date — the longest you have to wait — I'd say by the end of July… IF NOT BEFORE!
That's why next month, I'll be flying to Toronto, Canada to witness firsthand what I expect to be one of the biggest announcements in medical history...
If this company's new drug is declared a breakthrough drug, it will offer hope to the 5 million Americans plagued by Alzheimer's disease today.
And if the announcement goes the way I expect, this opportunity could also hand you the quickest double you've ever seen.
You could see gains of up to 100% in a matter of weeks.
But to take advantage of this urgent opportunity, you'll need to act quickly.
You see, a biotech company you've probably never heard of has developed a revolutionary new drug to potentially cure Alzheimer's disease…
And I believe this company is about to announce that regulators have agreed to let this drug's clinical trials end, way ahead of schedule… at the Alzheimer's Association International Conference I'll be attending in Toronto.
I'll cover this event firsthand... it'll be the lead story of my next issue.
The minute this announcement is made, I expect this company's stock to skyrocket...
And that's why I recommend you buy the stock FIRST, before the news breaks…
Because only those investors who get in EARLY can reap the biggest profits.
The catch?
As lucrative as I expect this opportunity to be for investors who establish a position today… it's "off limits" to most ordinary investors.
There are strict restrictions surrounding a potential investment in this company… meaning not everyone will be able to act on my recommendation.
First, you can't find this stock on the NYSE or Nasdaq. It only trades overseas.
But more importantly, an investment in this company requires a larger commitment than most other stocks.
You're required to buy at least 100 shares of the company. At current prices, that's a $6,000 investment, minimum.
This is a substantial amount of money for a speculative trade. And it's risky — one that shouldn't make up a significant portion of your portfolio…
And that's why only advanced investors, with larger portfolios should consider taking advantage of this urgent opportunity.
If that's not you, I apologize… but you should stop reading now.
However if this does sound like you, here's what you need to know…
This opportunity is more urgent than most that you're used to receiving from Stansberry Research, so I'll be brief…
Over the past few months, the CEO of this biotech company has been telling investors that clinical trials could stop, based on March 2016 data that showed real benefits to patients with Alzheimer's.
The CEO even said the trial could stop early, based on "the possibility for early clinical success."
The drug is currently in "Phase 2" – about halfway through the testing process.
>From there, a drug typically goes into Phase 3 trials before it can receive FDA approval.
But this statement indicates that the company believes this drug is working so well that the trial has already succeeded in proving its point.
>From the company's perspective, this drug works so well that it's now unethical for them to place anyone in the placebo group.
As soon as they stop trials, the company will track down every patient that it had been assigned to the placebo group… and made sure they received the actual drug, too.
The drug is simply that good.
Now here's why that matters…
Because of these results, the company asked the FDA for permission to end Phase 2 trials early. And I'm predicting the drug will receive designation from the FDA that will allow this to happen, expediting its development and review processes.
It's not often that this sort of request is granted… but it has happened before.
And I believe it's about to happen again.
And here's why that matters to investors…
The few times this scenario has occurred, the drug has almost always been fast-tracked for approval by the FDA.
In fact, this happened not long ago with Novartis' leukemia drug.
It received FDA approval based on results of three large phase 2 studies, which demonstrated just how successful it was at curing a widespread, deadly disease.
And investors who got in before that decision made out like bandits… Novartis' stock soared as high as 162% in the years that followed this early approval.
Now, Novartis is a big company...
But that ONE drug became a blockbuster – worth more than $1 billion in sales on fat margins.
Alzheimer's disease is also a multibillion-dollar market. And there's virtually no competition in the Alzheimer's drug space.
An estimated 5.4 million Americans currently have Alzheimer's. The direct and indirect costs of care today adds up to more than $236 billion every year, just in the United States.
Now consider this: The costs of treating Alzheimer's are almost entirely incurred by seniors who rely on Medicare – or in Europe, on their national health services' dime.
Meaning private companies or individual citizens won't pay for this new Alzheimer's treatment… the federal government would cover these costs.
Meanwhile, it's these same government regulators in the U.S. and Europe who are – we think – poised to confirm the early success of this company's specialized immunotherapy.
Given the huge social and economic costs of Alzheimer's, regulators face huge pressure to quickly approve new, effective drugs.
As of right now, approval has not yet been granted…
But this company's CEO recently just made another big move… one that signals to me that this drug's fast-tracked approval could come any minute now…
He just presented on how he's reorganizing the entire company's focus.
He shifted the company's focus away from most of its current business… approved drugs that are already profitable… to focus instead on untapped sectors of medicine like Alzheimer's.
It's is a bold move for a mature drug company with a dozen successful drugs already on the market… all for a drug that still hasn't received official approval from the FDA yet.
A bold move… unless the CEO expects that this drug is about to be approved.
And that’s why I'm reaching out to you with this urgent message today…
In short, I'm convinced that this company will receive permission from the FDA to end clinical trials of this drug early.
And because of this, I expect its Alzheimer's drug will be fast-tracked for approval… skipping Phase 3, and heading straight to market.
Now, I don't know how quickly this could happen.
It could happen tomorrow.
And of course, nothing is guaranteed. An announcement may never come.
On top of that, even if I'm right about the announcement, the stock may not behave like I expect.
So if you're unable to limit your position to a small percentage of your portfolio, you absolutely should not invest in this company.
This is a tiny, venture capital style investment, and it carries risks.
That said, I predict this company will make these announcements at the Alzheimer's Association International Conference that I'll be attending in July.
And here's why you have to act TODAY…
800-479-7881
Again, even though I expect this announcement to be made at the Alzheimer's conference… it could come even sooner.
Not to mention… as more and more people start putting the pieces of this story together – as I have laid out for you today – I won't be surprised to see this stock start creeping higher before the announcement is made…
Put another way, these rapid gains could begin at any point between now and when the company finally makes its announcement.
There's simply no way to know for sure.
But what you can be sure of is that when this story breaks, hedge funds, mutual funds, even ordinary investors who have never heard of this company will flood into this stock, sending its price soaring.
I expect it could shoot up as high as 100% on the news alone.
And that's you want to establish a position today…
Let me be clear: At heart, I'm not a speculator. For my newsletter, we follow a long-term buy-and-hold strategy.
But I follow science and medicine. And to me, this seems like an opportunity that's never come up before.
Alzheimer's is currently untreatable. We think that's about to change. And one company sits in the crossroads of this major development. It's that simple.
There's still reason to be cautious, though…
As I mentioned earlier, because of the unique requirements associated with this trade… it is most suitable for more experienced investors.
So I'm making a special offer to anyone who is interested in getting the specifics of this opportunity.
However, you must call my office directly to take part in that offer. And because of the urgency, you have to make the call this afternoon…
800-479-7881
I've asked our member services team to block out the rest of their day (until 3 P.M. ET)…
They're ready right now to field your calls, and explain the full details of this offer to you — to make sure it’s right for you.
They will help you get set up… and give you everything you need to act on this urgent opportunity immediately.
You see, this is the newest trade I've shared with readers of Stansberry Venture.
In case you're not already familiar with it, Stansberry Venture is our most elite investment research service.
It's designed for a small number of sophisticated readers, eager to put money behind early-stage venture capital opportunities like this.
My research is priced accordingly… in part to keep numbers small and ensure that only the most serious readers are let in.
There's another reason for this velvet rope, too: Covering advances in science, medicine, and technology around the globe for my team and me is expensive.
This year alone, we will spend tens of thousands of dollars hiring outside experts to confirm our research in the most innovative companies on the planet.
I focus almost exclusively on small to medium-sized firms that have enormous hidden potential, focusing mainly on cutting-edge themes… like new antibiotics against superbugs, immunotherapy to fight cancer, and high-end technology like bionics or deep-thinking machines.
So far, this strategy has been working…
My readers had the opportunity to lock in gains of 105%... 130%... and 140% – all within a few months — sometimes weeks — of an urgent buy recommendation just like the one I'm sending you today.
No wonder subscribers have flooded my inbox with comments like:
“Being up 50%... and 94%... pays for the subscription many times over. I couldn’t be more thrilled.” – Charles S.
“I would like to say that this subscription is the best offering at Stansberry & Associates.” – Dennis D.
“I bought [one of your recommendations] on 12/5 and sold on 12/18, pocketing about $11,000 profit.” – James R.
Of course I can’t guarantee that you'll be able to pocket $11,000 profit in just 13 days…
After all, the sort of money you make depends on how much you choose to invest in my recommendation.
But if gains like this… and research this sophisticated interests you… I’d like to invite you become a reader of Stansberry Venture today.
If you chose to invest, the urgent biotech opportunity I’ve outlined for you today is the first thing I suggest you to put your money in.
Again, this is the most promising opportunity I know of right now to potentially make up to 2X your money in a matter of weeks.
But unlike most of our newsletters, you can’t simply go to our website right now and sign up for details on how to take advantage of this opportunity...
The investment opportunities I share with readers of Stansberry Venture are meant for only the most serious and sophisticated investors.
And that’s why the ONLY way to sign up and learn how to take advantage of this opportunity right now is to call our member service team today:
800-479-7881
Our friendly Baltimore-based team will walk you through the offer.
If you call in, and decide you're interested in becoming a reader of Stansberry Venture today… they'll instantly e-mail you a copy of my urgent buy recommendation of this company: "How to Make up to 100% in Just a Few Days from the Specialized Immunotherapy to Treat Alzheimer’s."
This report includes even more details than I have the space to share with you here.
And it hands you the company's name, ticker symbol, and a buy-below price… so you can establish a position immediately.
But the only way to receive a copy of this report is by agreeing to become a reader of Stansberry Venture.
And the only way to do that is to call in today, and speak with one of our knowledgeable member services representatives, right now.
Here’s what to do…
Pick up your phone right now, and dial 800-479-7881.
You'll instantly be connected with a bright, college-educated man or woman based in our Baltimore offices. (We don’t route any of our calls to some miserable call center overseas. Your call goes straight to Stansberry HQ.)
Let them tell you about the special offer we’ve set up for you, so you’ll know how to take advantage of the urgent opportunity surrounding this Alzheimer’s drug.
If you’re not happy with your conversation… hang up. Total time commitment: 5 minutes or less.
On the other hand, if you want to move forward and take advantage of this urgent, potentially lucrative opportunity… you can get all the details by signing up to receive my report from the Alzheimer’s conference in Toronto – along with monthly issues featuring information and details on additional urgent opportunities like this — by simply agreeing to become a reader of Stansberry Venture.
Our representatives will be happy to answer any questions you may have about my research… and they’ll show you how to get started with my newsletter right away.
But again, I can’t stress this enough… the timing of this trade is crucial.
As I explained, missing out by even one day could eliminate the possibility of seeing the kinds of gains I expect investors who get into this company today will receive when this major announcement is made.
It's only a matter of time before more investors catch wind of the lucrative opportunity here.
So if you’re even the slightest bit interested, I urge you to take a few minutes to call our member service team today, before this window of opportunity closes.
Regards,
Dave Lashmet
Editor, Stansberry Venture
800-479-7881
P.S. One last thing I forgot to mention…
Because I'm so excited about the urgent opportunity you have to invest in this under-the-radar biotech company before it announces that its new Alzheimer's drug is being fast-tracked for approval…
I've arranged for a one-time-only way to claim an additional free year of Stansberry Venture, for those who take advantage of this offer and become a new reader today. This is your only shot to get the full details of this unique opportunity before this company’s announcement is made… at which point, I expect shares will shoot up as much as 100%.
So please, get off the computer… give us a call… and ask one of our friendly member service reps how you can get the details on this timely opportunity today.
They're looking forward to speaking with you.
Again, the number is:
800-479-7881
TDIL2 |
|
|
You are receiving this message as part of a subscribers-only e-mail service covering the worlds of investing, finance, and economics. You are receiving this email because you subscribe to one of the investment newsletters published by Stansberry & Associates Investment Research. PLEASE DO NOT REPLY DIRECTLY TO THIS EMAIL. To contact us for any reason, see the notice at the bottom of this message.
All contents of this e-mail are copyright 2016 by Stansberry & Associates Investment Research. All rights reserved. Reproducing any part of this document is prohibited without the express written consent of Porter Stansberry. Protected by U.S. Copyright Law {Title 17 U.S.C. Section 101 et seq., Title 18 U.S.C. Section 2319}: Infringements can be punishable by up to five years in prison and $250,000 in fines.
DISCLAIMER: The work included in this publication is based on SEC filings, current events, interviews, and corporate press releases. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The views expressed in this publication and on the DailyWealth website do not necessarily reflect the views of Stansberry & Associates Investment Research.
You're receiving this email at newsletter@newslettercollector.com. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry & Associates at (888) 261-2693 Monday-Friday between 9:00 a.m. and 5:00 p.m. Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry & Associates Investment Research, 1217 St. Paul Street Baltimore, MD 21202. If you wish to contact us by email, please do not reply to this message but instead go to info@stansberrycustomerservice.com.
To unsubscribe, click here.
|
|
|
